Third Rock Ventures

Last updated
Third Rock Ventures
Industry Venture capital
Founded2007
Headquarters Boston, Massachusetts, United States
Key people
Mark J. Levin
Kevin P. Starr
Robert I. Tepper
Website thirdrockventures.com

Third Rock Ventures is a venture capital firm with offices in Boston and San Francisco. [1] Founded in 2007, the firm invests in biotechnology startups. [2]

Contents

Funding and investments

Third Rock Ventures has raised $3.8 billion since it was created and invested in more than 60 companies, including Sage Therapeutics, Editas Medicine, Constellation Pharmaceuticals and Flare Therapeutics. [3] [4]

Related Research Articles

<span class="mw-page-title-main">Venture capital</span> Form of private-equity financing

Venture capital (VC) is a form of private equity financing that is provided by firms or funds to startup, early-stage, and emerging companies that have been deemed to have high growth potential or which have demonstrated high growth. Venture capital firms or funds invest in these early-stage companies in exchange for equity, or an ownership stake. Venture capitalists take on the risk of financing risky start-ups in the hopes that some of the companies they support will become successful. Because startups face high uncertainty, VC investments have high rates of failure. Start-ups are usually based on an innovative technology or business model and they are usually from high technology industries, such as information technology (IT), clean technology or biotechnology.

Sequoia Capital is an American venture capital firm headquartered in Menlo Park, California which specializes in seed stage, early stage, and growth stage investments in private companies across technology sectors. As of 2022, the firm had approximately US$85 billion in assets under management.

<span class="mw-page-title-main">Vertex Pharmaceuticals</span> American pharmaceutical company

Vertex Pharmaceuticals Incorporated is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry. It maintains headquarters in South Boston, Massachusetts, and three research facilities, in San Diego, California, and Milton Park, Oxfordshire, England.

Khosla Ventures is an American venture capital firm founded by Vinod Khosla, focused on early-stage companies in the Internet, computing, mobile, financial services, agriculture, healthcare and clean technology sectors. Some of its most successful investments include Affirm, DoorDash, Square, Impossible Foods, Instacart, and OpenAI.

<span class="mw-page-title-main">GV (company)</span> Venture capital unit of Alphabet Inc.

GV Management Company, L.L.C. is a venture capital investment arm of Alphabet Inc., founded by Bill Maris, that provides seed, venture, and growth stage funding to technology companies. Founded as Google Ventures in 2010, the firm has operated independently of Google, Alphabet's search and advertising division, since 2015. GV invests in startup companies in a variety of fields ranging from the Internet, software, and hardware to life science, healthcare, artificial intelligence, transportation, cyber security and agriculture. It has helped finance more than 300 companies that include Uber, Nest, Slack, and Flatiron Health.

Corporate venture capital (CVC) is the investment of corporate funds directly in external startup companies. CVC is defined by the Business Dictionary as the "practice where a large firm takes an equity stake in a small but innovative or specialist firm, to which it may also provide management and marketing expertise; the objective is to gain a specific competitive advantage." Examples of CVCs include GV and Intel Capital.

<span class="mw-page-title-main">Lux Capital</span> American venture capital firm

Lux Capital is a venture capital firm based in New York City. It was founded in 2000, and focuses on investments in emerging technologies.

Andreessen Horowitz is a private American venture capital firm, founded in 2009 by Marc Andreessen and Ben Horowitz. The company is headquartered in Menlo Park, California. As of April 2023, Andreessen Horowitz ranks first on the list of venture capital firms by assets under management, with $35 billion as of March 2022.

Alexion Pharmaceuticals, a subsidiary of AstraZeneca, is a pharmaceutical company headquartered in Boston, Massachusetts that specializes in orphan drugs to treat rare diseases.

<span class="mw-page-title-main">Ohio bioscience sector</span> Significant economic sector in the state

The Ohio bioscience sector strength was ranked #4 among USA states in 2008 by Business Facilities magazine.

<span class="mw-page-title-main">New Enterprise Associates</span> American Venture Capital firm

New Enterprise Associates (NEA) is an American-based venture capital firm. NEA focuses investment stages ranging from seed stage through growth stage across an array of industry sectors. With ~$25 billion in committed capital, NEA is one of the world's largest venture capital firms.

Atlas Venture is an early-stage venture capital firm that creates and invests in biotechnology startup companies in the U.S. Atlas is headquartered in Cambridge, Massachusetts, where the majority of its investments are located. Atlas raised its thirteenth fund totaling $450 million in March 2022, after raising its Opportunity Fund II totaling $300 million in September 2021.

Arie S. Belldegrun, FACS, is an Israeli-American urologic oncologist, billionaire businessman and investor.

<span class="mw-page-title-main">Moderna</span> American biotechnology company

Moderna, Inc. is a pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA (mRNA) to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".

<span class="mw-page-title-main">Editas Medicine</span> Discovery-phase pharmaceutical company

Editas Medicine, Inc.,, is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado.

<span class="mw-page-title-main">Pitango</span> Israeli venture capital fund

Pitango VC, established in 1993, is Israel's largest venture capital fund with over $2.8 billion under management. Pitango VC invests through three dedicated funds, Pitango First, Pitango HealthTech, and Pitango Growth. Pitango invests in startups around the world, in domains such as Vertical SaaS, Digital Health, Deep Tech, FinTech & InsureTech, Devops, Generative AI, Web3, and FoodTech.

Foresite Capital is an American venture capital and growth equity firm headquartered in San Francisco. As of March 2021, the company had raised five funds: Foresite Capital Fund I, II, III, IV and V.

<span class="mw-page-title-main">Biotechnology industry in Boston</span>

Greater Boston, primarily Boston and Cambridge, is home to more than 1,000 biotechnology companies, ranging from small start-ups to billion-dollar pharmaceutical companies. The many universities in the area give the region a large network of scientists.

Flagship Pioneering is an American life sciences venture capital company based in Cambridge, Massachusetts that invests in biotechnology, life sciences, health and sustainability companies. Portfolio companies include Moderna, Indigo Agriculture, Inari Agriculture and Novomer. The firm both funds and incubates companies.

<span class="mw-page-title-main">OrbiMed</span> American investment firm

OrbiMed is an American investment firm based in New York City, United States. It is focused on making public and private investments in the Healthcare and Biotechnology industries. OrbiMed is considered to be one of the largest dedicated healthcare investment firms in the world.

References

  1. DeAngelis, Allison. "Third Rock Ventures plots next chapter after raising $1.1 billion fund". STAT. Retrieved 16 April 2024.
  2. Timmeran, Luke (31 October 2016). "Third Rock Ventures, One of Biotech's Daring Investors, Raises $616M For More Startups". Forbes . Retrieved 22 August 2018.
  3. Terry, Mark. "In Tough Biotech Market, Third Rock Raises New $1.1B Fund". BioSpace. Retrieved 16 April 2024.
  4. DeAngelis, Allison. "Third Rock Ventures plots next chapter after raising $1.1 billion fund". STAT. Retrieved 16 April 2024.

Notes